Get notified when ARTL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and its auditor's report includes a going-concern explanatory paragraph.
- Nasdaq Delisting Risk (new) — The company has previously received delisting notices and is subject to a Mandatory Panel Monitor through April 6, 2027; failure to maintain compliance could result in delisting.
Artelo Biosciences launches $6.53M at-the-market offering at $1.19/share; no minimum raise
Filed May 26, 2026 · ~1 min read
Key Changes
-
high
Artelo Biosciences is offering up to $6.53 million of common stock through an at-the-market program with H.C. Wainwright as sales agent, at a 3.0% commission.
The Offering verify on EDGAR → -
high
The offering has no minimum amount, so actual proceeds are uncertain; net proceeds, if any, will fund product development and general corporate purposes.
Use of Proceeds verify on EDGAR → -
medium
New investors pay $1.19/share while pro forma net tangible book value is $1.33/share, resulting in $0.12 accretion per share for new investors.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade ARTL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify